Amplimune shown to lower incidence rates of clinical mastitis and metritis and improve pregnancy rates in dairy cows

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

MCWF (Amplimune) Shows Potential as a Preventative Treatment to Reduce Metritis Incidence in Dairy Cows

An abstract presented at the 2024 International Embryo Technology Society meeting summarizes a research study showing that a single treatment of Amplimune 7 days after parturition may help prevent metritis in dairy cows.

learn more

Settle® Now Available in Canada

Settle® immunotherapy for equine endometritis is now available in Canada. It's also sold in the USA, Australia, New Zealand and UAE. Settle is compatible with conventional treatments and is safe with natural breeding or AI.

learn more

Settle® Approved for Canadian Market

NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.

learn more

Follow NovaVive on Social Media.